CA
NZ
UK
AU
IND
US
Third-line NSCLC represents a particularly challenging treatment setting, as patients at this stage have typically already progressed through both chemotherapy and first-line immunotherapy or targeted treatment, leaving oncologists with a narrowing set of options and generally more modest expectations for disease control relative to …
The regulatory clarity comes on the heels of earlier Phase 2a data, presented in abstract form at the ARVO ophthalmology conference, that showed meaningful separation from placebo on patient-reported quality-of-life measures. Specifically, patients receiving urcosimod reported a mean change from baseline of −4.5 in …
ZORYVE, a topical phosphodiesterase-4 inhibitor, has already secured approvals in older age groups and related inflammatory skin conditions, giving Arcutis an established commercial and safety track record to lean on as it pursues this pediatric expansion. Extending the label to infants would meaningfully broaden …
Non-muscle invasive bladder cancer represents the majority of newly diagnosed bladder cancer cases and is characterized by a persistently high recurrence rate even after initial treatment, creating durable demand for new therapeutic options that can either reduce recurrence or provide effective salvage therapy for …
Valuing a clinical-stage or pre-commercial biotech ahead of a binary regulatory decision is an inherently probabilistic exercise, and Immunome's current market capitalization suggests investors are already assigning a fairly constructive probability to eventual approval, rather than treating the stock as a coin-flip proposition. That …
Beyond the imaging endpoint, the trial produced functional signals that investors found equally persuasive. Patients recorded a 34% mean increase in upper-limb effort alongside a 38% reduction in creatine kinase, a blood marker of muscle damage, while overall strength remained stable throughout the observation …
BASECAMP represents a meaningful expansion of scope for Satellos, moving the company's flagship asset from an adult population — where disease progression is often more advanced — into children, where regenerative therapies theoretically have more muscle tissue left to protect. The adult data, which …
The results suggested the GLIX1-olaparib pairing may sidestep that resistance problem. According to the companies, the combination successfully triggered synthetic lethality — a therapeutic effect in which two otherwise survivable cellular deficiencies become lethal in combination — even in tumors that would ordinarily evade …
Platinum-resistant gynecologic cancer represents one of oncology's more difficult treatment settings. Patients who progress after platinum-based chemotherapy — historically the backbone of ovarian cancer treatment — often face a narrowing set of options, with response rates to subsequent lines of therapy typically falling well …
Under the terms of the agreement, the merger is structured to advance nebokitug's ongoing Phase 2 clinical trial in rheumatoid arthritis, a disease area where precision-medicine tools like Scipher's could theoretically improve trial success rates by better matching patients to mechanism. Rheumatoid arthritis remains …
Please wait processing your request...